Katelin Katsis

Harvard University — United States

Medicine · Health Sciences

8h-index658citations19works7.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(7), SARS-CoV-2 and COVID-19 Research(5), COVID-19 Clinical Research Studies(3), Chronic Myeloid Leukemia Treatments(3), Myeloproliferative Neoplasms: Diagnosis and Treatment(3)

Publications19 total

Abstract 4621: Beyond tumor biomarkers: Multiparametric biophysical assessment of T cells from peripheral blood to inform checkpoint blockade therapy
Cancer Research·2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
Blood Advances·2025· 7 citedOpen Access
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Blood·2024· 17 citedOpen Access
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies
JCO Precision Oncology·2024· 4 citedOpen Access
Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
Blood·2022Open Access
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Nature Medicine·2022· 232 citedOpen Access
Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19
Diagnostics·2022· 10 citedOpen Access
Differential T cell immunity to SARS-CoV-2 in mRNA-1273 and BNT162b2 vaccinated individuals
The Journal of Immunology·2022· 1 cited
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphoma
2022· 20 citedOpen Access
Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273– and BNT162b2-Vaccinated Individuals
Clinical Infectious Diseases·2022· 8 citedOpen Access
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
Leukemia·2022· 4 citedOpen Access
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial
Blood·2022· 130 citedOpen Access
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
Blood Advances·2022· 21 citedOpen Access
Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma
Blood·2021· 5 cited
Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients
Blood·2021· 1 citedOpen Access
Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
Cell·2021· 164 citedOpen Access
SARS -CoV-2 T-cell immunity to variants of concern following vaccination
2021· 34 citedOpen Access
THE MODULATION OF FIBRINOGEN LEVELS BY GEMFIBROZIL IN HYPERTENSIVES WITH PRIMARY HYPERLIPIDAEMIA
Journal of Hypertension·2004
THE EFFECT OF GEMFIBROZIL AND FENOFIBRATE ON FIBRINOGEN LEVELS IN HYPERTENSIVES WITH PRIMARY HYPERLIPIDAEMIA
Journal of Hypertension·2004

Frequent Co-authors

Kathleen Gallagher(14), Marcela V. Maus(14), Mark B. Leick(10), Rebecca C. Larson(7), Matthew J. Frigault(6), Eva L. Elder(5), Trisha R. Berger(5), Nicholas J. Haradhvala(4), Daniella Cook(4), Nora Horick(4), Areej El‐Jawahri(4), Yi‐Bin Chen(4), Caron A. Jacobson(3), Gad Getz(3), Zachariah DeFilipp(3), Joan How(3), Yiwen Liu(3), Donna Neuberg(3), Gabriela Hobbs(3), Katie Maurer(2)